Each film-coated tablet contains Risperidone IP or BP in one of the following strengths: 1 mg, 2 mg, 3 mg or 4 mg.
Dosage form: Film-coated tablet
Therapeutic category: Second-generation (atypical) antipsychotic / CNS medicine
Website category: Anti Anxiety drugs (site taxonomy; not a primary anxiolytic indication)
Manufacturer: Healthy Life Pharma Pvt. Ltd. (certification subject to verification)
Exporter: Healthy Inc (export credentials subject to verification)
SKU: Risperidone Tablets
Risperidone Tablets ( – ) – Manufacturer & Exporter India is listed for pharmaceutical business-to-business enquiries. Exact active ingredients, formulation, strength, pack configuration and manufacturer details should be confirmed against the product label and approved technical documentation before ordering.
Categories: Pharmaceutical Exporter India · Pharmaceutical Formulations India · WHO GMP Certified Formulations
Risperidone is a prescription second-generation antipsychotic used in the management of schizophrenia, certain manic or mixed episodes associated with bipolar I disorder, and irritability associated with autistic disorder in specified patient populations, depending on local approval. It is not classified as an antidepressant and should not be advertised as a general anti-anxiety medicine.
Healthy Life Pharma Pvt. Ltd. is identified in the supplied information as manufacturer and Healthy Inc as exporter. WHO-GMP certification, facility location, production methods and supply-market authorisations require current supporting records.
| Standard | Available strength per film-coated tablet |
|---|---|
| Indian Pharmacopoeia (IP) | 1 mg, 2 mg, 3 mg, 4 mg |
| British Pharmacopoeia (BP) | 1 mg, 2 mg, 3 mg, 4 mg |
Generic name: Risperidone | CAS: 106266-06-2 | Class: Atypical antipsychotic. Packaging, shelf life, colours, imprints and market-specific standards must be confirmed from approved records.
Low-dose products require carefully validated blending, segregation controls, tablet weight control and content-uniformity testing. Particle-size management, granulation or direct compression and film-coating processes must be selected using formulation development and stability data. Claims about geometric mixing, micronisation, particular coating brands or colour coding should only be published if supported by batch records and approved product specifications.
Quality control should follow the applicable IP or BP monograph and approved finished-product specification. Typical assessments may include identification, assay, uniformity of dosage units, dissolution, related substances, microbial quality where relevant and stability. Do not publish a fixed assay range or dissolution percentage unless verified against the applicable monograph and registration dossier.
Risperidone acts primarily through dopamine D2 and serotonin 5-HT2A receptor antagonism. Depending on jurisdiction and patient characteristics, labelled indications can include schizophrenia, acute manic or mixed episodes of bipolar I disorder, and irritability associated with autistic disorder. It can cause movement-related adverse effects, especially at higher exposures, and is not free of extrapyramidal risk.
Importers and institutional buyers should request current manufacturing licence, applicable GMP certificate, market authorisation, product-specific certificates of analysis, approved labels, stability information and CTD/ACTD dossiers where available. Country-specific restrictions, packaging and supply arrangements require confirmation before procurement.
Risperidone 1 mg, 2 mg, 3 mg and 4 mg film-coated tablets are listed under both IP and BP standards.
No. Its primary pharmacological classification is an atypical antipsychotic. It should not be described as a general antidepressant or anti-anxiety treatment.
Yes. Weight, blood glucose and lipids may need monitoring because antipsychotic treatment can cause metabolic changes.
In the United States, risperidone carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis and is not approved for that use. Local product labelling must also be checked.
Prescription-only medicine. The starting dose, titration, maintenance dose and treatment duration depend on indication, age, renal or hepatic function, interacting medicines and local approved prescribing information. The supplied 1–4 mg tablets should not be assumed appropriate for every starting dose, especially paediatric or sensitive patients. Do not change or stop treatment without clinician guidance.
Adverse effects can include somnolence, dizziness, restlessness, tremor, stiffness, weight gain and increased prolactin. Clinically important risks include metabolic changes, orthostatic hypotension, tardive dyskinesia, neuroleptic malignant syndrome, swallowing problems and movement disorders. Elderly patients with dementia-related psychosis have increased mortality risk with antipsychotic medicines. Discuss pregnancy, breastfeeding, renal/hepatic impairment and interactions with the prescriber. Monitor as clinically indicated.
Store in the original packaging according to the approved product label and protect from inappropriate environmental exposure. The exact temperature range and shelf life must be supported by the approved label and stability dossier.
Information intended for healthcare professionals and B2B product enquiries. Certifications, strengths, indications and registration status must be confirmed for the destination market. Not a substitute for prescribing information.